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Since enzymes that degrade reactive oxygens, such as superoxide dismutase (SOD), are significantly lower in plasma than in intracellular compart- 
ments, cell surface membranes hould be protected against hazardous oxygens particularly when animals are challenged with oxidative stress. To 
minimize oxygen toxicity on endothelial cell surface, a fusion gene consisting of cDNA coding human Cu2+/Zn 2+-SOD and heparin-binding peptide 
was constructed and expressed in yeast. The resulting enzyme (HB-SOD) bound to a heparin-Sepharose column and cultured endothelial cells; 
binding was inhibited either by high NaCl concentrations or heparin. When injected intravenously, HB-SOD predominantly bound to vascular 
endothelial cell surface. Carrageenin-induced paw edema and cold-induced brain edema of the rat were markedly inhibited by a single dose of 
HB-SOD. These results suggest hat superoxide radical and/or its metabolite(s) occurring at or near the outer surface of vascular endothelial cells 
might play a critical role in the pathogenesis of vasogenic edema. 
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1. INTRODUCTION and inhibites cold-induced brain edema and carra- 
geenin-induced paw edema of the rat. 
Oxygen stress is one of the major impacts on aerobic 
life. Since most cells are highly enriched with antiox- 
idants and enzymes that degrade reactive oxygens [ 1,2], 
oxidative stress occurring inside cells can efficiently be 
minimized. Although similar enzymes are also present 
in plasma, such as extracellular SOD (EC-SOD) [3], 
their activities are significantly low. Thus, when tissues 
were challenged with high concentrations of extra- 
cellular reactive oxygens, membrane perturbation 
leading to cell injury might be triggered. Intravenously 
injected SOD decreases oxidative stress only briefly 
predominantly because of its rapid excretion in urine. 
EC-SOD has a specific binding site (consisting of 26 
amino acids) for heparin-like proteoglycans [4] and 
seems to be a potent inhibitor of oxygen toxicity. 
However, large scale xpression of recombinant EC- 
SOD sufficient for medical use has not been achieved 
yet presumably because of its glycoprotein nature [5]. 
2. MATERIALS AND METHODS 
2.1. Materials 
Conventional enzymes were obtained from Toyobo Co. Ltd 
(Osaka) and Takara Shuzo Co. Ltd (Kyoto). Evan’s blue, xanthine, 
xanthine oxidase, bovine SOD were purchased from Sigma Co. Ltd 
(Sr. Louis). Carrageenin was from Zushi Chemical Co. Ltd (Tokyo). 
‘Z51-Labeled Bolton-Hunter reagent (2.2 Ci/mol) was from New 
England Nuclear Co. Ltd. (Boston). 
2.2. Construction of a fusion gene encoding HB-SOD 
To overcome such frustrating situations, a fusion 
gene encoding human Cu2+/Zn2+-SOD having a C- 
terminal heparin-binding domain (HB-SOD) was con- 
structed and expressed in yeast. The present work 
demonstrates that HB-SOD specifically binds to 
heparin-like proteoglycans on endothelial cell surface 
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A fusion gene encoding HB-SOD consisting of human Cuzi 
/Zn*+-SOD and a C-terminal heparin-binding peptide with 26 amino 
acids similar to the heparin-binding domain of EC-SOD was con- 
structed and expressed in yeast essentially as described previously [6]. 
Briefly, a full length of human SOD cDNA was obtained from a 
human placenta cDNA library [7]. A restriction site of EcoRI was 
made just before the initiation codon by site-directed mutagenesis IS]. 
About 450 bp EcoRI-Sau3AI fragment of SOD gene was subcloned 
into EcoRI-BamHI sites of pBR322 and the constructed plasmid was 
denoted as pBRSOD. A nucleotide fragment, which encoded heparin 
binding peptide of EC-SOD with a stop codon and restriction sites of 
Sau3AI and San, was constructed by annealing four synthetic nucleo- 
tides, S’GATCTGCGGGCCCGGGATCTGGGAGCGCCAGGCG- 
CGGGAGCACT3’ (Fr. A), S’TCTTGCGCTCTGAGTGCTCCCG- 
CGCCTGGCGCTCCCAGATCCCGGGCCCGCA3 ’ (Fr. B), 
5’CAGAGCGCAAGAAGCGGCGGCGCGAGAGCGAGTGCAA- 
GGCCGCCTGAG3 ’ (Fr. C), and 5 ’ TCGACTCAGGCGGCCTTG- 
CACTCGCTCTCGCGCCGCCGCT3’ (Fr. D) as described pre- 
viously [9]. The constructed fragments were ligated with about 4.5 kb 
BamHI-Sall fragments of pBRSOD and the constructed plasmid was 
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denoted aspBRHBSOD. pBRHBSOD contained the HB-SOD gene 
encoding SOD having the heparin binding peptide with 26 amino 
acids on its C-terminal portion. About 0.5 kb EcoRI-Sufi fragment of 
pBRHBSOD was ligated with 8.0 kb EcoRI-SalI fragment of a yeast 
expression vector pYHCClO1 [lo] and the constructed plasmid was 
denoted as pYHBS1. pYHBS1 contained TRPZ as a selectable marker 
for yeast and HB-SOD gene in the plasmid was controlled by 
glyceraldehyde-3-phosphate d hydrogenase promotor in yeast. A 
yeast strain EHl3-15 (Mat cu, frpl) [1 l] was transformed by pYHBS1 
as described [12]. Fig. 1 shows the diagram for the construction of 
HB-SOD gene and the structure of HB-SOD. 
2.3. Purification of HB-SOD 
The transformants were cultivated in Burkholder medium [13] and 
the expression of HB-SOD was confirmed immunologically using 
anti-SOD antibody; about 5% of cellular protein was found to be HB- 
SOD. Following heat treatment and chromatography on SP- 
Sephadex A-50, heparin-Sepharose and Sephadex G-75 columns, 
about 300 mg of HB-SOD was purified from 300 g of cells. Purifica- 
tion of HB-SOD by affinity chromatography on heparin-Sepharose 
was carried out essentially as described previously [14]; under 
physiological salt concentrations, HB-SOD, but not SOD, bound to 
the heparin-Sepharose column and was eluted by 1 M NaCl. Apparent 
molecular masses of 21000 and 40000 were obtained for HB-SOD by 
SDS-polyacrylamide gel electrophoresis and Sephadex G-75 column 
chromatography under nondenaturing conditions, respectively; 
specific activity of HB-SOD was 1500 unit/mg protein as determined 
by cytochrome c method [ 151. Analysis by gas-phase sequencer sug- 
gested that the N-terminal amino acid of HB-SOD was also acetylated 
as was native SOD [ 161. SOD and HB-SOD revealed similar stability 
to heat treatment; more than 90% of enzyme activity remained after 
treating with 70°C for 10 min. HB-SOD samples thus obtained were 
dissolved in phosphate buffered saline (pH 7.4) and were stored at 
- 80°C until use; under such conditions, the enzyme can be stored at 
least for 6 months without decreasing its catalytic activity. 
2.4. Binding to endothelial cell surface 
Endothelial cells were isolated from freshly obtained bovine aorta 
by trypsin digestion, cultured in Eagle’s minimum essential medium 
(MEM) containing 5% fetal calf serum, and were used for experi- 
ments 2 days after confluent as described previously [ 171. Binding of 
‘251-labeled HB-SOD and SOD to endothelial cell surface was deter- 
mined at 4°C in Eagle’s MEM as described previously [18]. 
2.4. In vivo experiments 
Male Sprague-Dawley rats, 200-210 g, were used for experiments 
after fasting for 15 h. Under light ether anesthesia, animals were sub- 




Fig, 1. Construction of plasmid pYHBS1 and structure of HB-SOD. 
Spotted area represents human Cu*+/Zn*+-SOD cDNA and solid area 
(HB) represents cDNA for the heparin-binding peptide. Open area 
represents the TRPI and IR genes of plasmid pYHBS1. Thin line 
represents plasmid pBR322 DNA. Pgap, glyceraldehyde-3-phosphate 
dehydrogenase promoter; AC-A, acetylated N-terminal alanine of 
SOD and HB-SOD; Fr. A-D, synthetic DNA fragments. heparin; squares, native SOD. 
Fig. 2. Inhibition of HB-SOD binding to endothelial eel1 surface by 
heparin. Cultured endothelial cells from porcine aorta (2 days after 
confluence) were incubated in 2 ml Eagle’s MEM [17] with 3 rg/ml of 
radioactive SOD or HB-SOD (1.2 x 104 and 1.4x 104 cpm/pg protein, 
respectively) in the presence or absence of 56Org/ml heparin at 0°C. 
At the indicated times after incubation, cells were washed with 3 ml 
of ice-cold MEM for 3 times and determined for cell-associated 
radioactivity. Open circles, HB-SOD; closed circles, HB-SOD + 
cutaneously injected with 0.1 ml of carrageenin dissolved in saline 
solution (10 mg/kg). The volume of the paw was measured by using 
a Plethysmometer (Unicorn Model TK-101). 
Under pentobarbital anesthesia (50 mg/kg), cold-induced brain 
edema was induced essentially as described previously [ 191. 
3. RESULTS AND DISCUSSION 
3.1. Binding of HB-SOD to endothelial cell surface 
To test whether HB-SOD having a C-terminal basic 
domain might specifically bind to vascular endothelial 
cell surface, the radiolabeled enzyme samples were in- 
cubated with cultured endothelial cells. As shown in 
Fig. 2, HB-SOD bound to the cell surface of cultured 
endothelial cells. Since endothelial cells were enriched 
with acidic proteoglycans, such as heparan sulfate [20], 
the binding was also determined in the presence of 
heparin. As expected, binding of HB-SOD to en- 
dothelial cell surface was completely inhibited by the 
presence of heparin. Same concentration of chondroitin 
sulfate failed to inhibit the binding (data not shown). 
Under identical conditions, native SOD did not bind to 
vascular endothelial cells. Preliminary experiments 
revealed that intravenously injected HB-SOD 
predominantly localized on the lumenal surface of 
vascular endothelial cells [21]. Thus, superoxide 
radicals on the outer surface of vascular endothelial 
cells would efficiently be dismutated by membrane- 
bound HB-SOD. It has been well documented that sub- 
cutaneous injection of carrageenin, a potent inducer of 
local inflammation, increases the permeability of 
vascular endothelial cells and induces paw edema of the 
rat 122-251. To test whether dismutation of superoxide 
radicals close to the outer surface of endothelial cells 
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Fig. 3. Effect of HB-SOD on carrageenin-induced paw edema. Under 
light ether anesthesia, rats were intravenously administered 0.2 ml of 
saline (open circles) or 5 mg/kg of HB-SOD (closed circles). After 5 
min, 2 mg of carrageenin in 0.1 ml saline was ~bcutan~us~y injected 
in the paw. At the inducated times after injection, the paw volume 
was measured by a plethysmometer (Unicorn Model TK-101). Values 
show the increased paw volume (%I of initial level) and are expressed 
as mean t SD derived from 4-6 rats. 
might protect tissues from being attacked by oxygen 
radicals, the effect of HB-SOD was tested on 
carrageenin-induced paw edema (Fig. 3). The volume 
of the paw increased with time after carrageenin injec- 
tion. The paw edema was inhibited significantly by a 
single dose of HB-SOD. Thus, superoxide and/or its 
metabolite~s) might be responsible for the carra- 
geenjn-induced increase in vascular permeability. 
To test whether reactive oxygens also play a critical 
role in vasogenic edema of other tissues, such as the 
brain, effect of HB-SOD was also observed on cold- 
induced brain edema. As shown in Fig. 4, HB-SOD 
markedly inhibited brain edema. Equimolar amounts 
of SOD, heat-denatured HB-SOD and the heparin- 
Fig. 4. Effect of FIB-SOD on cold-induced brain edema. Under light 
ether anesthesia, animals were intravenously injected with 0.2 ml 
sahne (left) or 5 mg/kg HB-SOD (right). After 5 min, cold-injury was 
induced at the right hemisphere of the brain (arrow) by applying a 
liquid-~trogen~cold plasticine probe (20 g, 4 mm in diameter) to the 
right side of the bony skull for 20 s. Two hours after giving cold- 
injury, animals were intravenously injected with 0.2 ml of 1% Eva&s 
blue. After 30 min, the animal was exsanguinated by bleeding and the 
brain was excised. 
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binding peptide failed to inhibit paw edema and brain 
edema at any conditions tested. These results suggested 
that superoxide radical and/or its metabolite(s) on the 
outer surface of vascular endothelial cells might play a 
critical role in the pathogenesis of vasogenic edema. 
Preliminary experiments revealed that HB-SOD also in- 
hibited the lethal arrh~hmias elicited by occluding the 
left anterior deseending artery of the rat and decreased 
the mortality from 60% to 22%. Thus, superoxide 
radical and/its metabolite(s) might also be involved in 
various types of vasogenic diseases, such as ischemic 
myocardiai injury, 
Since HB-SOD consisted of human type of Cuzf/ 
Znzi-SOD and the heparin-binding domain of EC-SOD 
and can easily be expressed in yeast with large amounts, 
HB-SOD may be useful for protecting vascular endo- 
thelial cells {and parenchymal cells) against oxygen toxi- 
city without immunoiogi~al compfications. This metho- 
dology provides a new strategy for targeting enzymes 
and bioactive peptides to the subcellular site(s) where 
heparin-like proteoglycans are enriched and permits 
molecular studies on pathological events occurring at or 
near the vascular endothelial cell surface. 
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